methoxsalen has been researched along with Scleroderma, Systemic in 14 studies
Methoxsalen: A naturally occurring furocoumarin compound found in several species of plants, including Psoralea corylifolia. It is a photoactive substance that forms DNA ADDUCTS in the presence of ultraviolet A irradiation.
methoxsalen : A member of the class of psoralens that is 7H-furo[3,2-g]chromen-7-one in which the 9 position is substituted by a methoxy group. It is a constituent of the fruits of Ammi majus. Like other psoralens, trioxsalen causes photosensitization of the skin. It is administered topically or orally in conjunction with UV-A for phototherapy treatment of vitiligo and severe psoriasis.
Scleroderma, Systemic: A chronic multi-system disorder of CONNECTIVE TISSUE. It is characterized by SCLEROSIS in the SKIN, the LUNGS, the HEART, the GASTROINTESTINAL TRACT, the KIDNEYS, and the MUSCULOSKELETAL SYSTEM. Other important features include diseased small BLOOD VESSELS and AUTOANTIBODIES. The disorder is named for its most prominent feature (hard skin), and classified into subsets by the extent of skin thickening: LIMITED SCLERODERMA and DIFFUSE SCLERODERMA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One patient with generalized morphea had stopped EP after 3 months because of loss of vascular access and could not be evaluated." | 2.68 | Extracorporeal photochemotherapy in systemic sclerosis and severe morphea. ( Cribier, B; Faradji, T; Grosshans, E; Le Coz, C; Oberling, F, 1995) |
| "Seventy-nine patients with systemic sclerosis of recent onset (mean symptom duration, 1." | 2.67 | Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial. ( Barr, WG; Freundlich, B; Jegasothy, BV; Jimenez, SA; Kahaleh, MB; Perez, MI; Rietschel, RL; Rook, AH; Varga, J; Wintroub, B, 1992) |
| "Nine patients with active progressive systemic sclerosis were treated with extracorporeal photochemotherapy on 2 successive days monthly." | 1.29 | Extracorporeal photochemotherapy in progressive systemic sclerosis. ( Bisaccia, E; Cahill, C; Cottrill, C; Degnan, E; Di Spaltro, FX; Franks, AJ; Klainer, AS; Mulford, GJ; Scarborough, D, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 8 (57.14) | 18.2507 |
| 2000's | 2 (14.29) | 29.6817 |
| 2010's | 4 (28.57) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Papp, G | 1 |
| Horvath, IF | 1 |
| Barath, S | 1 |
| Gyimesi, E | 1 |
| Vegh, J | 1 |
| Szodoray, P | 1 |
| Zeher, M | 1 |
| Samimi, S | 1 |
| Rook, AH | 2 |
| Hayashi, S | 1 |
| Ikeda, M | 1 |
| Kitamura, Y | 1 |
| Hamasaki, Y | 1 |
| Hatamochi, A | 1 |
| Trautinger, F | 1 |
| Just, U | 1 |
| Knobler, R | 1 |
| Hashikabe, M | 1 |
| Ohtsuka, T | 1 |
| Yamazaki, S | 1 |
| Di Spaltro, FX | 1 |
| Cottrill, C | 1 |
| Cahill, C | 1 |
| Degnan, E | 1 |
| Mulford, GJ | 1 |
| Scarborough, D | 1 |
| Franks, AJ | 1 |
| Klainer, AS | 1 |
| Bisaccia, E | 1 |
| Cribier, B | 1 |
| Faradji, T | 1 |
| Le Coz, C | 1 |
| Oberling, F | 1 |
| Grosshans, E | 1 |
| Morison, WL | 1 |
| Balogh, A | 2 |
| Merkel, U | 2 |
| Looks, A | 2 |
| Vollandt, R | 2 |
| Wollina, U | 2 |
| Zic, JA | 1 |
| Miller, JL | 1 |
| Stricklin, GP | 1 |
| King, LE | 1 |
| Muellegger, RR | 1 |
| Hofer, A | 1 |
| Salmhofer, W | 1 |
| Soyer, HP | 1 |
| Kerl, H | 1 |
| Wolf, P | 1 |
| Freundlich, B | 1 |
| Jegasothy, BV | 1 |
| Perez, MI | 1 |
| Barr, WG | 1 |
| Jimenez, SA | 1 |
| Rietschel, RL | 1 |
| Wintroub, B | 1 |
| Kahaleh, MB | 1 |
| Varga, J | 1 |
| Trentham, DE | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effectiveness of ECP in Diffuse Cutaneous Systemic Sclerosis[NCT04986605] | Phase 2 | 15 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for methoxsalen and Scleroderma, Systemic
| Article | Year |
|---|---|
Photopheresis (extracorporeal photochemotherapy).
Topics: Graft Rejection; Graft vs Host Disease; Humans; Lymphoma, T-Cell, Cutaneous; Methoxsalen; Photophere | 2013 |
The North American experience with photopheresis.
Topics: Arthritis, Rheumatoid; Graft vs Host Disease; Humans; Lymphoma, T-Cell, Cutaneous; Methoxsalen; Nort | 1999 |
6 trials available for methoxsalen and Scleroderma, Systemic
| Article | Year |
|---|---|
Quantitative echographic analysis of photochemotherapy on systemic sclerosis skin.
Topics: Adult; Aged; Dermis; Female; Humans; Male; Methoxsalen; Middle Aged; Photopheresis; Scleroderma, Sys | 2005 |
Extracorporeal photochemotherapy in systemic sclerosis and severe morphea.
Topics: Adolescent; Adult; Aged; Arthritis; Disease Progression; Drug Tolerance; Esophageal Diseases; Female | 1995 |
Plasma and buffy coat concentration of 8-methoxypsoralen in patients treated with extracorporeal photopheresis.
Topics: Adult; Aged; Aged, 80 and over; Area Under Curve; Female; Humans; Leukapheresis; Lymphoma, T-Cell; M | 1998 |
Drug monitoring of orally administered 8-methoxypsoralen in patients treated with extracorporeal photopheresis.
Topics: Adult; Area Under Curve; Female; Humans; Lymphoma, T-Cell; Male; Methoxsalen; Middle Aged; Photopher | 1998 |
Extended extracorporeal photochemotherapy with extracorporeal administration of 8-methoxypsoralen in systemic sclerosis. An Austrian single-center study.
Topics: Adult; Aged; Austria; Combined Modality Therapy; Female; Humans; Methoxsalen; Middle Aged; Photochem | 2000 |
Treatment of systemic sclerosis with extracorporeal photochemotherapy. Results of a multicenter trial.
Topics: Adult; Aged; Combined Modality Therapy; Female; Humans; Immunotherapy; Leukapheresis; Leukocytes; Ma | 1992 |
6 other studies available for methoxsalen and Scleroderma, Systemic
| Article | Year |
|---|---|
Immunomodulatory effects of extracorporeal photochemotherapy in systemic sclerosis.
Topics: Adult; Case-Control Studies; Combined Modality Therapy; Cytokines; Female; Humans; Male; Methoxsalen | 2012 |
The relevance of photopheresis to autoreactive diseases.
Topics: Cytokines; Female; Humans; Male; Methoxsalen; Photopheresis; Scleroderma, Systemic | 2012 |
UVA irradiation following treatment with topical 8-methoxypsoralen improves bleomycin-induced scleroderma in a mouse model, by reducing the collagen content and collagen gene expression levels in the skin.
Topics: Administration, Cutaneous; Animals; Bleomycin; Collagen Type I; Collagen Type III; Disease Models, A | 2012 |
Extracorporeal photochemotherapy in progressive systemic sclerosis.
Topics: Activities of Daily Living; Adult; Aged; Female; Humans; Kidney; Leukapheresis; Lung; Male; Methoxsa | 1993 |
Psoralen UVA therapy for linear and generalized morphea.
Topics: Adolescent; Adult; Dermatitis, Phototoxic; Female; Follow-Up Studies; Humans; Male; Methoxsalen; Mid | 1997 |
Photochemotherapy in systemic sclerosis. The stage is set.
Topics: Humans; Leukocytes; Methoxsalen; Penicillamine; Photochemotherapy; Scleroderma, Systemic; Ultraviole | 1992 |